Medical cannabis is expected to reach 56.7B market value by 2026. On this episode we hear from Oxford Cannabinoid Technologies co-founders Neil Mahapatra (Kingsley Capital Partners, Rothschild, Morgan Stanley) and Gavin Sathianathan (Alta Flora

Why Drug Discovery Is Getting More Expensive And How To Fix It With Structural Genomics Consortium Chief Scientist Chas Bountra

Nov 5th, 2019 33m 53s

Reverse Moore's Law: drug discovery gets more expensive every year. On the Oxford Biotech Podcast we talk to Professor Chas Bountra, former head of biology at GSK, about the new open-source solution he is developing to bring down the costs of l

The Future of Gene Editing and How to Beat CRISPR with TargetGene CEO Yoel Shiboleth and COO Dan Weinthal

Oct 7th, 2019 44m 55s

Two colleagues began engineering RNA-guided nucleases before CRISPR-Cas9 was ever used for gene editing. We visited them in Israel to learn about their startup, the booming gene editing industry, and how they might just beat CRISPR at its own g

How CRISPR-Chip will change DNA detection with Prof Kiana Aran of Nanosens Innovations and Keck Graduate Institute

Aug 26th, 2019 19m 39s

Prof Kiana Aran walks us through the invention and applications of CRISPR-Chip - her celebrated invention that enables sequence-specific real-time detection of DNA without amplification or complex sample processing. CRISPR-Chip: https://ww

The Algae Biotech Bubble, Strain Engineering, and Early Stage Startup Experience with Dr Jonathan Meuser and Prof Robert Jinkerson of Chi Botanic

Aug 19th, 2019 40m 10s

Why the algae biofuels bubble burst and what comes next; the future directions of strain engineering; reflections on starting an early stage plant science biotech. Robert's Lab: http://jinkersonlab.engr.ucr.edu/Music from: https://frees

Spider Silk Ties and Synthetic Biology Materials of the Future with Bolt Thread's CSO David Breslauer

Aug 2nd, 2019 29m 21s

The biochemical secrets to spider silk's strength; producing artificial spider's silk using synthetic biology; why Bolt chose apparel - and their plan to translate science into sales; how to win The Bay Area Top Workplace Award three years in a

Graphene Biosensors and the San Diego Ecosystem with Cardea's CEO Michael Heltzen and CTO Brett Goldsmith

Jul 1st, 2019 38m 57s

The emerging technology of graphene biosensors; Cardea's commercialisation strategy that enabled it to succeed in nano where decades of industry attempts had failed; what the San Diego biotech ecosystem offers that is attracting biotech entrepr

Rate